SMYD3 is frequently overexpressed in a wide variety of cancers. Indeed, its inactivation reduces tumor growth in preclinical in vivo animal models. However, extensive characterization in vitro failed to clarify SMYD3 function in cancer cells, although confirming its importance in carcinogenesis. Taking advantage of a SMYD3 mutant variant identified in a high-risk breast cancer family, here we show that SMYD3 phosphorylation by ATM enables the formation of a multiprotein complex including ATM, SMYD3, CHK2, and BRCA2, which is required for the final loading of RAD51 at DNA double-strand break sites and completion of homologous recombination (HR). Remarkably, SMYD3 pharmacological inhibition sensitizes HR-proficient cancer cells to PARP inhibitors, thereby extending the potential of the synthetic lethality approach in human tumors.

Targeting SMYD3 to sensitize homologous recombination-proficient tumors to PARP-mediated synthetic lethality / Sanese, P.; Fasano, C.; Buscemi, G.; Bottino, C.; Corbetta, S.; Fabini, E.; Silvestri, V.; Valentini, V.; Disciglio, V.; Forte, G.; Lepore Signorile, M.; De Marco, K.; Bertora, S.; Grossi, V.; Guven, U.; Porta, N.; Di Maio, V.; Manoni, E.; Giannelli, G.; Bartolini, M.; Del Rio, A.; Caretti, G.; Ottini, L.; Simone, C.. - In: ISCIENCE. - ISSN 2589-0042. - 23:10(2020). [10.1016/j.isci.2020.101604]

Targeting SMYD3 to sensitize homologous recombination-proficient tumors to PARP-mediated synthetic lethality

Silvestri V.;Valentini V.;De Marco K.;Porta N.;Di Maio V.;Ottini L.;
2020

Abstract

SMYD3 is frequently overexpressed in a wide variety of cancers. Indeed, its inactivation reduces tumor growth in preclinical in vivo animal models. However, extensive characterization in vitro failed to clarify SMYD3 function in cancer cells, although confirming its importance in carcinogenesis. Taking advantage of a SMYD3 mutant variant identified in a high-risk breast cancer family, here we show that SMYD3 phosphorylation by ATM enables the formation of a multiprotein complex including ATM, SMYD3, CHK2, and BRCA2, which is required for the final loading of RAD51 at DNA double-strand break sites and completion of homologous recombination (HR). Remarkably, SMYD3 pharmacological inhibition sensitizes HR-proficient cancer cells to PARP inhibitors, thereby extending the potential of the synthetic lethality approach in human tumors.
2020
cancer; cell biology; molecular biology
01 Pubblicazione su rivista::01a Articolo in rivista
Targeting SMYD3 to sensitize homologous recombination-proficient tumors to PARP-mediated synthetic lethality / Sanese, P.; Fasano, C.; Buscemi, G.; Bottino, C.; Corbetta, S.; Fabini, E.; Silvestri, V.; Valentini, V.; Disciglio, V.; Forte, G.; Lepore Signorile, M.; De Marco, K.; Bertora, S.; Grossi, V.; Guven, U.; Porta, N.; Di Maio, V.; Manoni, E.; Giannelli, G.; Bartolini, M.; Del Rio, A.; Caretti, G.; Ottini, L.; Simone, C.. - In: ISCIENCE. - ISSN 2589-0042. - 23:10(2020). [10.1016/j.isci.2020.101604]
File allegati a questo prodotto
File Dimensione Formato  
Sanese_Targeting-SMYD3_2020.pdf

accesso aperto

Note: https://www.sciencedirect.com/science/article/pii/S2589004220307963
Tipologia: Versione editoriale (versione pubblicata con il layout dell'editore)
Licenza: Creative commons
Dimensione 2.34 MB
Formato Adobe PDF
2.34 MB Adobe PDF

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11573/1446097
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 13
  • ???jsp.display-item.citation.isi??? 14
social impact